Somnolence in adult craniopharyngioma patients is a common, heterogeneous condition that is potentially treatable.
Authors
Crowley, R KWoods, C
Fleming, M
Rogers, B
Behan, L A
O'Sullivan, E P
Kane, T
Agha, A
Smith, D
Costello, R W
Thompson, C J
Affiliation
Department of Academic Endocrinology, Beaumont Hospital, Dublin 9, Ireland.Issue Date
2011-06
Metadata
Show full item recordCitation
Somnolence in adult craniopharyngioma patients is a common, heterogeneous condition that is potentially treatable. 2011, 74 (6):750-5 Clin. Endocrinol. (Oxf)Journal
Clinical endocrinologyDOI
10.1111/j.1365-2265.2011.03993.xPubMed ID
21521265Additional Links
http://www.ncbi.nlm.nih.gov/pubmed/21521265Abstract
Somnolence and obesity are prevalent in craniopharyngioma patients. We hypothesized that somnolence was because of obstructive sleep apnoea in craniopharyngioma patients.We assessed prevalence of somnolence and sleep apnoea in 28 craniopharyngioma and 23 obese controls attending a tertiary referral centre, by means of the Epworth Sleepiness Score (ESS) and polysomnography. All subjects with sleep apnoea were offered continuous positive airway pressure therapy (CPAP) or modafinil. All craniopharyngioma patients, with unexplained somnolence, were offered modafinil.
Somnolence was reported by 20/28 (71·5%) craniopharyngioma patients and 4/23 (17%) obese subjects (P < 0·001). Median ESS was 7·5 (IQR 6, 10·7) in craniopharyngioma patients and 4·0 (4,8) in controls, P < 0·01. Eleven somnolent craniopharyngioma patients had obstructive sleep apnoea, in whom treatment led to a reduction in ESS by 6·4 ± 1·4, P = 0·01. Among the remaining nine patients, five were offered modafinil therapy, of whom four had benefit, three were not compliant with hormone replacement, and one died before intervention. There was no difference in the prevalence of obstructive sleep apnoea between craniopharyngioma (n = 13, 46%) and obese subjects (n = 14, 61%, P = 0·4). Body mass index (BMI) does not correlate with apnoea hypopnoea index [apnoea - hypopnoea index (AHI), r = 0·25, P = 0·08], which suggests that obesity alone does not explain the prevalence of sleep apnoea in craniopharyngioma patients.
Somnolence is common in craniopharyngioma patients and in the majority is because of obstructive sleep apnoea. An additional group of somnolent craniopharyngioma patients benefits from modafinil.
Item Type
ArticleLanguage
enISSN
1365-2265ae974a485f413a2113503eed53cd6c53
10.1111/j.1365-2265.2011.03993.x
Scopus Count
Collections
Related articles
- Placebo and modafinil effect on sleepiness in obstructive sleep apnea.
- Authors: Bittencourt LR, Lucchesi LM, Rueda AD, Garbuio SA, Palombini LO, Guilleminault C, Tufik S
- Issue date: 2008 Feb 15
- Modafinil improves daytime sleepiness in patients with mild to moderate obstructive sleep apnoea not using standard treatments: a randomised placebo-controlled crossover trial.
- Authors: Chapman JL, Kempler L, Chang CL, Williams SC, Sivam S, Wong KK, Yee BJ, Grunstein RR, Marshall NS
- Issue date: 2014 Mar
- Effects of armodafinil in the treatment of residual excessive sleepiness associated with obstructive sleep apnea/hypopnea syndrome: a 12-week, multicenter, double-blind, randomized, placebo-controlled study in nCPAP-adherent adults.
- Authors: Roth T, White D, Schmidt-Nowara W, Wesnes KA, Niebler G, Arora S, Black J
- Issue date: 2006 May
- [The effect of CPAP treatment on excessive daytime somnolence in patients with obstructive sleep apnea].
- Authors: Bednarek M, Zgierska A, Pływaczewski R, Zieliński J
- Issue date: 1999
- Sleepiness and Sleep-related Breathing Disorders in Myotonic Dystrophy and Responses to Treatment: A Prospective Cohort Study.
- Authors: West SD, Lochmüller H, Hughes J, Atalaia A, Marini-Bettolo C, Baudouin SV, Anderson KN
- Issue date: 2016 Nov 29